Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2026)

Aquestive Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $110.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 61.29% year-over-year to $110.7 million; the TTM figure through Mar 2026 stood at $110.7 million (up 61.29% YoY), while the FY2025 annual figure was $121.2 million, up 69.36% from the prior year.
• Cash & Equivalents was $110.7 million for Q1 2026 at Aquestive Therapeutics, down from $121.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $129.1 million in Q3 2025 to a low of $14.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $58.9 million across 5 years, with a median of $60.5 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 48.31% in 2022, then soared 300.56% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $27.3 million in 2022, then dropped by 12.47% to $23.9 million in 2023, then surged by 199.71% to $71.5 million in 2024, then surged by 69.36% to $121.2 million in 2025, then dropped by 8.61% to $110.7 million in 2026.
• The last three Cash & Equivalents figures came in at $110.7 million (Q1 2026), $121.2 million (Q4 2025), and $129.1 million (Q3 2025), per Business Quant data.